Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. 2021;:caac.21660.

Bai R, Chen N, Li L, Du N, Bai L, Lv Z, et al. Mechanisms of Cancer Resistance to Immunotherapy. Front Oncol. 2020;10:1290.

pubmed: 32850400 pmcid: 7425302 doi: 10.3389/fonc.2020.01290

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18:59.

pubmed: 32264958 pmcid: 7140346 doi: 10.1186/s12964-020-0530-4

Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, et al. Cancer Development, Progression, and Therapy: an epigenetic overview. IJMS. 2013;14:21087–113.

pubmed: 24152442 pmcid: 3821660 doi: 10.3390/ijms141021087

Hanahan D. Hallmarks of Cancer: New dimensions. Cancer Discov. 2022;12:31–46.

pubmed: 35022204 doi: 10.1158/2159-8290.CD-21-1059

Chew V, Toh HC, Abastado J-P. Immune Microenvironment in Tumor Progression: characteristics and challenges for Therapy. J Oncol. 2012;2012:1–10.

doi: 10.1155/2012/608406

Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131.

pubmed: 34635121 pmcid: 8504100 doi: 10.1186/s12943-021-01428-1

Butti R, Kumar TVS, Nimma R, Banerjee P, Kundu IG, Kundu GC. Osteopontin Signaling in shaping Tumor Microenvironment Conducive to Malignant Progression. In: Birbrair A, editor. Tumor Microenvironment. Cham: Springer International Publishing; 2021. pp. 419–41.

doi: 10.1007/978-3-030-73119-9_20

Andersson P, Yang Y, Hosaka K, Zhang Y, Fischer C, Braun H, et al. Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasis. JCI Insight. 2018;3:e122375.

pubmed: 30333314 pmcid: 6237443 doi: 10.1172/jci.insight.122375

Butti R, Nimma R, Kundu G, Bulbule A, Kumar TVS, Gunasekaran VP, et al. Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression. Oncogene. 2021;40:2002–17.

pubmed: 33603163 doi: 10.1038/s41388-021-01663-2

Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267–84.

pubmed: 30275043 pmcid: 6169832 doi: 10.1101/gad.314617.118

Sadeghalvad M, Mohammadi-Motlagh H-R, Rezaei N. Immune microenvironment in different molecular subtypes of ductal breast carcinoma. Breast Cancer Res Treat. 2021;185:261–79.

pubmed: 33011829 doi: 10.1007/s10549-020-05954-2

Del Gil CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, et al. Immune escape in breast Cancer during in situ to Invasive Carcinoma Transition. Cancer Discov. 2017;7:1098–115.

doi: 10.1158/2159-8290.CD-17-0222

Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The Crosstalk between Tumor Cells and the Immune Microenvironment in breast Cancer: implications for Immunotherapy. Front Oncol. 2021;11:610303.

pubmed: 33777750 pmcid: 7991834 doi: 10.3389/fonc.2021.610303

Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–50.

pubmed: 15229479 doi: 10.1038/nrc1388

Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. npj Breast Cancer. 2023;9:7.

pubmed: 36781869 pmcid: 9925769 doi: 10.1038/s41523-023-00508-3

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–50.

pubmed: 29686425 pmcid: 5998822 doi: 10.1038/s41591-018-0014-x

Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular classifications of Triple-negative breast Cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176–98.

pubmed: 30679171 pmcid: 6387871 doi: 10.1158/2159-8290.CD-18-1177

Stark MC, Joubert AM, Visagie MH. Molecular Farming of Pembrolizumab and Nivolumab. IJMS. 2023;24:10045.

pubmed: 37373192 pmcid: 10298108 doi: 10.3390/ijms241210045

Krasniqi E, Barchiesi G, Pizzuti L, Mazzotta M, Venuti A, Maugeri-Saccà M, et al. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. J Hematol Oncol. 2019;12:111.

pubmed: 31665051 pmcid: 6820969 doi: 10.1186/s13045-019-0798-2

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast Cancer. N Engl J Med. 2020;382:810–21.

pubmed: 32101663 doi: 10.1056/NEJMoa1910549

Adel NG. Current treatment landscape and emerging therapies for metastatic triple-negative breast cancer. Am J Manag Care. 2021;27(Suppl 5):S87–96.

pubmed: 33856160 doi: 10.37765/ajmc.2021.88626

Franzoi MA, Romano E, Piccart M. Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann Oncol. 2021;32:323–36.

pubmed: 33307202 doi: 10.1016/j.annonc.2020.11.022

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau H-T, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–86.

pubmed: 29063313 doi: 10.1007/s10549-017-4537-5

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.

pubmed: 22437870 pmcid: 4856023 doi: 10.1038/nrc3239

Henriques B, Mendes F, Martins D. Immunotherapy in breast Cancer: when, how, and what challenges? Biomedicines. 2021;9:1687.

pubmed: 34829916 pmcid: 8616011 doi: 10.3390/biomedicines9111687

Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58–67.

pubmed: 29118008 doi: 10.1182/blood-2017-06-741033

Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98–106.

pubmed: 26558876 pmcid: 4892769 doi: 10.1097/COC.0000000000000239

Shimomura A, Fujiwara Y, Kondo S, Kodaira M, Iwasa S, Kitano S, et al. Tremelimumab-associated tumor regression following after initial progression: two case reports. Immunotherapy. 2016;8:9–15.

pubmed: 26427600 doi: 10.2217/imt.15.89

Tarhini A. CTLA-4 blockade: therapeutic potential in cancer treatments. OTT. 2010;3:15–25.

Loi S, Francis PA, Zdenkowski N, Gebski V, Fox SB, White M, et al. Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): a single-arm phase 2 trial. JCO. 2022;40 16suppl:602–602.

doi: 10.1200/JCO.2022.40.16_suppl.602

Santa-Maria CA, Kato T, Park J-H, Kiyotani K, Rademaker A, Shah AN, et al. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget. 2018;9:18985–96.

pubmed: 29721177 pmcid: 5922371 doi: 10.18632/oncotarget.24867

Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018;15:477–94.

pubmed: 29872177 doi: 10.1038/s41571-018-0046-7

Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different Immune checkpoint inhibitor regimens: a systematic review and Meta-analysis. JAMA Oncol. 2018;4:173.

pubmed: 28973656 doi: 10.1001/jamaoncol.2017.3064

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of Chemotherapy plus a monoclonal antibody against HER2 for metastatic breast Cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

pubmed: 11248153 doi: 10.1056/NEJM200103153441101

Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, et al. Interplay between natural killer cells and Anti-HER2 antibodies: perspectives for breast Cancer immunotherapy. Front Immunol. 2017;8:1544.

pubmed: 29181007 pmcid: 5694168 doi: 10.3389/fimmu.2017.01544

Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22:1139–50.

doi: 10.1016/S1470-2045(21)00288-6

Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2 + breast cancer therapies. Am J Cancer Res. 2020;10:1045–67.

pubmed: 32368385 pmcid: 7191090

García-Aranda M, Redondo M, Immunotherapy. A challenge of breast Cancer Treatment. Cancers. 2019;11:1822.

pubmed: 31756919 pmcid: 6966503 doi: 10.3390/cancers11121822

Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart MJ, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2020;122:603–12.

pubmed: 31839676 doi: 10.1038/s41416-019-0635-y

Nuti M, Bellati F, Visconti V, Napoletano C, Domenici L, Caccetta J, et al. Immune effects of Trastuzumab. J Cancer. 2011;2:317–23.

pubmed: 21716848 pmcid: 3119394 doi: 10.7150/jca.2.317

Klein P. Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol. 2003;30:49–53.

pubmed: 14613026 doi: 10.1053/j.seminoncol.2003.08.007

Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive metastatic breast Cancer. N Engl J Med. 2015;372:724–34.

pubmed: 25693012 pmcid: 5584549 doi: 10.1056/NEJMoa1413513

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, et al. Pembrolizumab plus Trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncol. 2019;20:371–82.

pubmed: 30765258 doi: 10.1016/S1470-2045(18)30812-X

Royce M, Osgood CL, Amatya AK, Fiero MH, Chang CJG, Ricks TK, et al. FDA approval Summary: Margetuximab plus Chemotherapy for Advanced or metastatic HER2-Positive breast Cancer. Clin Cancer Res. 2022;28:1487–92.

pubmed: 34916216 pmcid: 9012688 doi: 10.1158/1078-0432.CCR-21-3247

Rugo HS, Im S-A, Cardoso F, Cortés J, Curigliano G, Musolino A, et al. Efficacy of Margetuximab vs Trastuzumab in patients with pretreated ERBB2-Positive advanced breast Cancer: a phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7:573.

pubmed: 33480963 doi: 10.1001/jamaoncol.2020.7932

Tarantino P, Morganti S, Uliano J, Giugliano F, Crimini E, Curigliano G. Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opin Biol Ther. 2021;21:127–33.

pubmed: 33238772 doi: 10.1080/14712598.2021.1856812

Jiao X, Wang M, Zhang Z, Li Z, Ni D, Ashton AW, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021;23:11.

pubmed: 33485378 pmcid: 7825185 doi: 10.1186/s13058-021-01391-1

Behl A, Wani ZA, Das NN, Parmar VS, Len C, Malhotra S, et al. Monoclonal antibodies in breast cancer: a critical appraisal. Crit Rev Oncol/Hematol. 2023;183:103915.

pubmed: 36702424 doi: 10.1016/j.critrevonc.2023.103915

Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101–26.

pubmed: 36344672 doi: 10.1038/s41573-022-00579-0

Hamilton EP, Petit T, Pistilli B, Goncalves A, Ferreira AA, Dalenc F, et al. Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs. JCO. 2020;38 15suppl:3093–3093.

doi: 10.1200/JCO.2020.38.15_suppl.3093

Zhang J, Ji D, Cai L, Yao H, Yan M, Wang X, et al. First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast Cancer: results from a phase I study. Clin Cancer Res. 2022;28:618–28.

pubmed: 34844975 doi: 10.1158/1078-0432.CCR-21-2827

Peters C, Brown S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35:e00225.

pubmed: 26182432 pmcid: 4613712 doi: 10.1042/BSR20150089

Arab A, Yazdian-Robati R, Behravan J. HER2-Positive breast Cancer Immunotherapy: a focus on Vaccine Development. Arch Immunol Ther Exp. 2020;68:2.

doi: 10.1007/s00005-019-00566-1

Galván Morales MA, Barrera Rodríguez R, Santiago Cruz JR, Teran LM. Overview of new treatments with immunotherapy for breast Cancer and a proposal of a combination therapy. Molecules. 2020;25:5686.

pubmed: 33276556 pmcid: 7730494 doi: 10.3390/molecules25235686

Keam SJ. Trastuzumab Deruxtecan: first approval. Drugs. 2020;80:501–8.

pubmed: 32144719 doi: 10.1007/s40265-020-01281-4

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic Landscape of Endocrine-Resistant Advanced breast cancers. Cancer Cell. 2018;34:427–e4386.

pubmed: 30205045 pmcid: 6327853 doi: 10.1016/j.ccell.2018.08.008

Rugo HS, Bianchini G, Cortes J, Henning J-W, Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022;7:100553.

pubmed: 35964548 pmcid: 9375150 doi: 10.1016/j.esmoop.2022.100553

Chiu JWY, Lee SC, Ho JC, Park YH, Chao T-C, Kim S-B, et al. Clinical Guidance on the monitoring and management of Trastuzumab Deruxtecan (T-DXd)-Related adverse events: insights from an Asia-Pacific Multidisciplinary Panel. Drug Saf. 2023;46:927–49.

pubmed: 37552439 pmcid: 10584766 doi: 10.1007/s40264-023-01328-x

Sussman D, Smith LM, Anderson ME, Duniho S, Hunter JH, Kostner H, et al. SGN–LIV1A: a novel antibody–drug Conjugate Targeting LIV-1 for the treatment of metastatic breast Cancer. Mol Cancer Ther. 2014;13:2991–3000.

pubmed: 25253783 doi: 10.1158/1535-7163.MCT-13-0896

Modi S, Pusztai L, Forero A, Mita M, Miller K, Weise A, et al. Abstract PD3-14: phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer. Cancer Res. 2018;78(4Supplement):PD3–14.

Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, et al. Sacituzumab Govitecan (IMMU-132), an Anti-TROP2/SN-38 antibody–drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26:919–31.

pubmed: 25915780 doi: 10.1021/acs.bioconjchem.5b00223

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, et al. Efficacy and safety of Anti-TROP2 antibody drug Conjugate Sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast Cancer. J Clin Oncol. 2017;35:2141–8.

pubmed: 28291390 pmcid: 5559902 doi: 10.1200/JCO.2016.70.8297

Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP2: clinical development in metastatic breast cancer. Breast. 2022;66:169–77.

pubmed: 36302269 pmcid: 9614644 doi: 10.1016/j.breast.2022.10.007

Dent RA, Cescon DW, Bachelot T, Jung KH, Shao Z-M, Saji S, et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023;19:2349–59.

pubmed: 37526149 doi: 10.2217/fon-2023-0228

Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, et al. EMERGE: a randomized phase II study of the antibody-drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing breast Cancer. JCO. 2015;33:1609–19.

doi: 10.1200/JCO.2014.56.2959

Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, et al. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (METRIC): a randomized multicenter study. npj Breast Cancer. 2021;7:57.

pubmed: 34016993 pmcid: 8137923 doi: 10.1038/s41523-021-00244-6

D’Arienzo A, Verrazzo A, Pagliuca M, Napolitano F, Parola S, Viggiani M, et al. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. eClinicalMedicine. 2023;62:102113.

pubmed: 37554126 pmcid: 10404866 doi: 10.1016/j.eclinm.2023.102113

Clifton GT, Peoples GE, Mittendorf EA. The development and use of the E75 (HER2 369–377) peptide vaccine. Future Oncol. 2016;12:1321–9.

pubmed: 27044454 pmcid: 6040084 doi: 10.2217/fon-2015-0054

Clifton GT, Gall V, Peoples GE, Mittendorf EA. Clinical Development of the E75 vaccine in breast Cancer. Breast Care (Basel). 2016;11:116–21.

pubmed: 27239173 doi: 10.1159/000446097

Brown TA, Mittendorf EA, Hale DF, Myers JW, Peace KM, Jackson DO, et al. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020;181:391–401.

pubmed: 32323103 pmcid: 7188712 doi: 10.1007/s10549-020-05638-x

Zhao L, Zhang M, Cong H. Advances in the study of HLA-restricted epitope vaccines. Hum Vaccin Immunother. 2013;9:2566–77.

pubmed: 23955319 pmcid: 4162067 doi: 10.4161/hv.26088

Clifton GT, Mittendorf EA, Peoples GE. Adjuvant HER2/neu peptide cancer vaccines in breast cancer. Immunotherapy. 2015;7:1159–68.

pubmed: 26567563 doi: 10.2217/imt.15.81

Mittendorf EA, Clifton GT, Holmes JP, Schneble E, Van Echo D, Ponniah S, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25:1735–42.

pubmed: 24907636 pmcid: 4143091 doi: 10.1093/annonc/mdu211

Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol. 2016;27:1241–8.

pubmed: 27029708 pmcid: 4922316 doi: 10.1093/annonc/mdw150

Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, et al. NY-ESO-1 based immunotherapy of Cancer: current perspectives. Front Immunol. 2018;9:947.

pubmed: 29770138 pmcid: 5941317 doi: 10.3389/fimmu.2018.00947

Wang C, Gu Y, Zhang K, Xie K, Zhu M, Dai N, et al. Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. Nat Commun. 2016;7:10499.

pubmed: 26813108 pmcid: 4737856 doi: 10.1038/ncomms10499

O’Shaughnessy J, Roberts LK, Smith JL, Levin MK, Timis R, Finholt JP, et al. Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts). JCO. 2016;34 15suppl:1086–1086.

doi: 10.1200/JCO.2016.34.15_suppl.1086

Higgins M, Curigliano G, Dieras V, Kuemmel S, Kunz G, Fasching PA, et al. Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive stage II/III breast cancer: a randomized phase I study. Breast Cancer Res Treat. 2017;162:479–88.

pubmed: 28176175 pmcid: 5332485 doi: 10.1007/s10549-017-4130-y

Chung VM, Kos F, Hardwick N, Yuan Y, Chao J, Li M, et al. A phase 1 study of p53MVA vaccine in combination with pembrolizumab. JCO. 2018;36 5suppl:206–206.

doi: 10.1200/JCO.2018.36.5_suppl.206

Kimura T, Finn OJ. MUC1 immunotherapy is here to stay. Expert Opin Biol Ther. 2013;13:35–49.

pubmed: 22998452 doi: 10.1517/14712598.2012.725719

Hosseini M, Seyedpour S, Khodaei B, Loghman A-H, Seyedpour N, Yazdi M-H, et al. Cancer vaccines for Triple-negative breast Cancer: a systematic review. Vaccines. 2023;11:146.

pubmed: 36679991 pmcid: 9866612 doi: 10.3390/vaccines11010146

Rugo HS, Cortes J, Xu B, Huang C-S, Kim S-B, Melisko ME, et al. A phase 3, randomized, open-label study of the anti-globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer. JCO. 2022;40 16suppl:TPS611–611.

doi: 10.1200/JCO.2022.40.16_suppl.TPS611

Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to Triple-negative breast Cancer. Cancer Res. 2013;73:2025–30.

pubmed: 23536562 pmcid: 3654815 doi: 10.1158/0008-5472.CAN-12-1699

Gray A, Yan L, Kast WM. Prevention is Better Than cure: the case for clinical trials of Therapeutic Cancer vaccines in the prophylactic setting. Mol Interv. 2010;10:197–203.

pubmed: 20729485 pmcid: 2965609 doi: 10.1124/mi.10.4.2

Brito Baleeiro R, Liu P, Chard Dunmall LS, Di Gioia C, Nagano A, Cutmore L, et al. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer. J Immunother Cancer. 2023;11:e007336.

pubmed: 37586771 pmcid: 10432671 doi: 10.1136/jitc-2023-007336

Zhang S, Liu Y, Zhou J, Wang J, Jin G, Wang X. Breast Cancer Vaccine containing a Novel toll-like receptor 7 agonist and an aluminum adjuvant exerts Antitumor effects. IJMS. 2022;23:15130.

pubmed: 36499455 pmcid: 9741412 doi: 10.3390/ijms232315130

Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stöger H, Pichler A, et al. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). Eur J Cancer. 2020;132:43–52.

pubmed: 32325419 doi: 10.1016/j.ejca.2020.03.018

Dehghan-Manshadi M, Nikpoor AR, Hadinedoushan H, Zare F, Sankian M, Fesahat F, et al. Protective immune response against P32 oncogenic peptide-pulsed PBMCs in mouse models of breast cancer. Int Immunopharmacol. 2021;93:107414.

pubmed: 33578183 doi: 10.1016/j.intimp.2021.107414

Basu A, Albert GK, Awshah S, Datta J, Kodumudi KN, Gallen C, et al. Identification of immunogenic MHC class II Human HER3 peptides that mediate Anti-HER3 CD4 + Th1 responses and potential use as a Cancer Vaccine. Cancer Immunol Res. 2022;10:108–25.

pubmed: 34785506 doi: 10.1158/2326-6066.CIR-21-0454

Callmann CE, Cole LE, Kusmierz CD, Huang Z, Horiuchi D, Mirkin CA. Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer. Proc Natl Acad Sci USA. 2020;117:17543–50.

pubmed: 32669433 pmcid: 7395518 doi: 10.1073/pnas.2005794117

Huang L, Rong Y, Tang X, Yi K, Qi P, Hou J, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer. 2022;21:45.

pubmed: 35148751 pmcid: 8831689 doi: 10.1186/s12943-022-01515-x

Tay AS-MS, Amano T, Edwards LA, Yu JS. CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper T cell responses against breast cancer stem cells. Mol Therapy - Oncolytics. 2021;22:64–71.

doi: 10.1016/j.omto.2021.05.006

Liu L, Wang Y, Miao L, Liu Q, Musetti S, Li J, et al. Combination immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade effectively inhibits growth of Triple negative breast Cancer. Mol Ther. 2018;26:45–55.

pubmed: 29258739 doi: 10.1016/j.ymthe.2017.10.020

Santisteban M, Solans BP, Hato L, Urrizola A, Mejías LD, Salgado E, et al. Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis. Ther Adv Med Oncol. 2021;13:175883592110646.

doi: 10.1177/17588359211064653

Maeng HM, Moore BN, Bagheri H, Steinberg SM, Inglefield J, Dunham K, et al. Phase I clinical trial of an autologous dendritic cell vaccine against HER2 shows Safety and preliminary clinical efficacy. Front Oncol. 2021;11:789078.

pubmed: 34976830 pmcid: 8716407 doi: 10.3389/fonc.2021.789078

Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, et al. Dendritic cell vaccination enhances Immune responses and induces regression of HER2pos DCIS Independent of Route: results of Randomized Selection Design Trial. Clin Cancer Res. 2017;23:2961–71.

pubmed: 27965306 doi: 10.1158/1078-0432.CCR-16-1924

Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, et al. Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER

pubmed: 28932627 doi: 10.1080/2162402X.2016.1207032

Bernal-Estévez DA, Ortíz Barbosa MA, Ortíz-Montero P, Cifuentes C, Sánchez R, Parra-López CA. Autologous dendritic cells in Combination with Chemotherapy restore responsiveness of T cells in breast Cancer patients: a single-arm phase I/II trial. Front Immunol. 2021;12:669965.

pubmed: 34489928 pmcid: 8417880 doi: 10.3389/fimmu.2021.669965

Adams S, Kozhaya L, Martiniuk F, Meng T-C, Chiriboga L, Liebes L, et al. Topical TLR7 agonist Imiquimod can induce Immune-mediated rejection of skin metastases in patients with breast Cancer. Clin Cancer Res. 2012;18:6748–57.

pubmed: 22767669 pmcid: 3580198 doi: 10.1158/1078-0432.CCR-12-1149

Salazar LG, Lu H, Reichow JL, Childs JS, Coveler AL, Higgins DM, et al. Topical Imiquimod Plus Nab-paclitaxel for breast Cancer cutaneous metastases: a phase 2 clinical trial. JAMA Oncol. 2017;3:969.

pubmed: 28114604 pmcid: 5824239 doi: 10.1001/jamaoncol.2016.6007

Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814–24.

pubmed: 30962585 doi: 10.1038/s41591-019-0410-x

Dees S, Ganesan R, Singh S, Grewal IS. Emerging CAR-T cell therapy for the treatment of Triple-negative breast Cancer. Mol Cancer Ther. 2020;19:2409–21.

pubmed: 33087511 doi: 10.1158/1535-7163.MCT-20-0385

Dey A, Ghosh S, Jha S, Hazra S, Srivastava N, Chakraborty U, et al. Recent advancement in breast cancer treatment using CAR T cell therapy:- a review. Adv Cancer Biology - Metastasis. 2023;7:100090.

doi: 10.1016/j.adcanc.2023.100090

Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121:837–45.

pubmed: 31570753 pmcid: 6889154 doi: 10.1038/s41416-019-0578-3

Schepisi G, Gianni C, Palleschi M, Bleve S, Casadei C, Lolli C, et al. The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) cell and macrophage (CAR-M) therapy against breast Cancer. Cancers. 2023;15:1597.

pubmed: 36900394 pmcid: 10000829 doi: 10.3390/cancers15051597

Raftery MJ, Franzén AS, Radecke C, Boulifa A, Schönrich G, Stintzing S, et al. Next Generation CD44v6-Specific CAR-NK cells effective against Triple negative breast Cancer. IJMS. 2023;24:9038.

pubmed: 37240385 pmcid: 10218876 doi: 10.3390/ijms24109038

Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16:97.

pubmed: 37596653 pmcid: 10439661 doi: 10.1186/s13045-023-01492-8

Long B, Brem E, Koyfman A. Oncologic emergencies: Immune-Based Cancer therapies and complications. WestJEM. 2020;21:566–80.

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95.

pubmed: 24876563 pmcid: 4093680 doi: 10.1182/blood-2014-05-552729

Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255–73.

pubmed: 33264547 pmcid: 7727315 doi: 10.1056/NEJMra2026131

Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Sig Transduct Target Ther. 2021;6:218.

doi: 10.1038/s41392-021-00641-0

Simon T, Salhia B. Cancer-Associated fibroblast subpopulations with diverse and dynamic roles in the Tumor Microenvironment. Mol Cancer Res. 2022;20:183–92.

pubmed: 34670861 pmcid: 9306405 doi: 10.1158/1541-7786.MCR-21-0282

Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al. IL1-Induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9:282–301.

pubmed: 30366930 doi: 10.1158/2159-8290.CD-18-0710

Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20212–7.

pubmed: 24277834 pmcid: 3864274 doi: 10.1073/pnas.1320318110

Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu C-C, Simpson TR, et al. Depletion of Carcinoma-Associated fibroblasts and fibrosis induces immunosuppression and accelerates Pancreas Cancer with reduced survival. Cancer Cell. 2014;25:719–34.

pubmed: 24856586 pmcid: 4180632 doi: 10.1016/j.ccr.2014.04.005

Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of Antitumor immunity by stromal cells expressing fibroblast activation Protein–α. Science. 2010;330:827–30.

pubmed: 21051638 doi: 10.1126/science.1195300

Hu D, Li Z, Zheng B, Lin X, Pan Y, Gong P, et al. Cancer-associated fibroblasts in breast cancer: challenges and opportunities. Cancer Commun. 2022;42:401–34.

doi: 10.1002/cac2.12291

Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18:792–804.

pubmed: 34489603 pmcid: 8791784 doi: 10.1038/s41571-021-00546-5

Wu SZ, Roden DL, Wang C, Holliday H, Harvey K, Cazet AS et al. Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. EMBO J. 2020;39:e104063.

Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast Cancer. Cancer Cell. 2018;33:463–e47910.

pubmed: 29455927 doi: 10.1016/j.ccell.2018.01.011

Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-cell analysis reveals fibroblast clusters linked to Immunotherapy Resistance in Cancer. Cancer Discov. 2020;10:1330–51.

pubmed: 32434947 doi: 10.1158/2159-8290.CD-19-1384

Chen L, Qiu X, Wang X, He J. FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression. Biochem Biophys Res Commun. 2017;487:8–14.

pubmed: 28302482 doi: 10.1016/j.bbrc.2017.03.039

Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W, et al. FAP promotes immunosuppression by Cancer-Associated fibroblasts in the Tumor Microenvironment via STAT3–CCL2 signaling. Cancer Res. 2016;76:4124–35.

pubmed: 27216177 doi: 10.1158/0008-5472.CAN-15-2973

Cords L, Tietscher S, Anzeneder T, Langwieder C, Rees M, De Souza N, et al. Cancer-associated fibroblast classification in single-cell and spatial proteomics data. Nat Commun. 2023;14:4294.

pubmed: 37463917 pmcid: 10354071 doi: 10.1038/s41467-023-39762-1

Cremasco V, Astarita JL, Grauel AL, Keerthivasan S, MacIsaac K, Woodruff MC, et al. FAP delineates heterogeneous and functionally divergent stromal cells in Immune-excluded breast tumors. Cancer Immunol Res. 2018;6:1472–85.

pubmed: 30266714 pmcid: 6597261 doi: 10.1158/2326-6066.CIR-18-0098

Rivas EI, Linares J, Zwick M, Gómez-Llonin A, Guiu M, Labernadie A, et al. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2 + breast tumors. Nat Commun. 2022;13:5310.

pubmed: 36085201 pmcid: 9463158 doi: 10.1038/s41467-022-32782-3

Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9:4692.

pubmed: 30410077 pmcid: 6224529 doi: 10.1038/s41467-018-06654-8

Liu X, Lu Y, Huang J, Xing Y, Dai H, Zhu L, et al. CD16 + fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition. Cancer Cell. 2022;40:1341–e135713.

pubmed: 36379207 doi: 10.1016/j.ccell.2022.10.015

Dominguez CX, Müller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15 + myofibroblasts as a determinant of patient response to Cancer Immunotherapy. Cancer Discov. 2020;10:232–53.

pubmed: 31699795 doi: 10.1158/2159-8290.CD-19-0644

Grauel AL, Nguyen B, Ruddy D, Laszewski T, Schwartz S, Chang J, et al. TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts. Nat Commun. 2020;11:6315.

pubmed: 33298926 pmcid: 7725805 doi: 10.1038/s41467-020-19920-5

Yoshikawa K, Ishida M, Yanai H, Tsuta K, Sekimoto M, Sugie T. Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer. BMC Cancer. 2021;21:239.

pubmed: 33676425 pmcid: 7937297 doi: 10.1186/s12885-021-07970-x

Yokoyama T, Komori A, Nakamura M, Takii Y, Kamihira T, Shimoda S, et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL‐8 via the TLR4‐NF‐κB and ‐MAPK signaling pathways. Liver Int. 2006;26:467–76.

pubmed: 16629651 doi: 10.1111/j.1478-3231.2006.01254.x

Steele NG, Biffi G, Kemp SB, Zhang Y, Drouillard D, Syu L, et al. Inhibition of hedgehog signaling alters fibroblast composition in pancreatic Cancer. Clin Cancer Res. 2021;27:2023–37.

pubmed: 33495315 pmcid: 8026631 doi: 10.1158/1078-0432.CCR-20-3715

Zheng S, Zou Y, Tang Y, Yang A, Liang J-Y, Wu L, et al. Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer. OncoImmunology. 2022;11:2020984.

pubmed: 35003899 pmcid: 8741292 doi: 10.1080/2162402X.2021.2020984

Zheng S, Liang J, Tang Y, Xie J, Zou Y, Yang A et al. Dissecting the role of cancer-associated fibroblast‐derived biglycan as a potential therapeutic target in immunotherapy resistance: a tumor bulk and single‐cell transcriptomic study. Clin Translational Med. 2023;13:e1189.

Deligne C, Midwood KS. Macrophages and extracellular matrix in breast Cancer: partners in crime or protective allies? Front Oncol. 2021;11:620773.

pubmed: 33718177 pmcid: 7943718 doi: 10.3389/fonc.2021.620773

Qiu S-Q, Waaijer SJH, Zwager MC, de Vries EGE, van der Vegt B, Schröder CP. Tumor-associated macrophages in breast cancer: innocent bystander or important player? Cancer Treat Rev. 2018;70:178–89.

pubmed: 30227299 doi: 10.1016/j.ctrv.2018.08.010

Arora S, Dev K, Agarwal B, Das P, Syed MA. Macrophages: their role, activation and polarization in pulmonary diseases. Immunobiology. 2018;223:383–96.

pubmed: 29146235 doi: 10.1016/j.imbio.2017.11.001

Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.

Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–96.

pubmed: 20856220 doi: 10.1038/ni.1937

Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.

pubmed: 12401408 doi: 10.1016/S1471-4906(02)02302-5

Su S, Liu Q, Chen J, Chen J, Chen F, He C, et al. A positive Feedback Loop between Mesenchymal-Like Cancer cells and macrophages is essential to breast Cancer metastasis. Cancer Cell. 2014;25:605–20.

pubmed: 24823638 doi: 10.1016/j.ccr.2014.03.021

Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res. 2015;17:101.

pubmed: 26243145 pmcid: 4531540 doi: 10.1186/s13058-015-0621-0

Xu M, Liu M, Du X, Li S, Li H, Li X, et al. Intratumoral Delivery of IL-21 overcomes Anti-Her2/Neu resistance through shifting Tumor-Associated macrophages from M2 to M1 phenotype. J Immunol. 2015;194:4997–5006.

pubmed: 25876763 doi: 10.4049/jimmunol.1402603

Ruffell B, Coussens LM. Macrophages and therapeutic resistance in Cancer. Cancer Cell. 2015;27:462–72.

pubmed: 25858805 pmcid: 4400235 doi: 10.1016/j.ccell.2015.02.015

Fu L-Q, Du W-L, Cai M-H, Yao J-Y, Zhao Y-Y, Mou X-Z. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol. 2020;353:104119.

pubmed: 32446032 doi: 10.1016/j.cellimm.2020.104119

Dong F, Ruan S, Wang J, Xia Y, Le K, Xiao X, et al. M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2. Cell Death Dis. 2020;11:728.

pubmed: 32908134 pmcid: 7481779 doi: 10.1038/s41419-020-02926-8

Cendrowicz E, Sas Z, Bremer E, Rygiel TP. The role of macrophages in Cancer Development and Therapy. Cancers. 2021;13:1946.

pubmed: 33919517 pmcid: 8073377 doi: 10.3390/cancers13081946

Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399–416.

pubmed: 28117416 pmcid: 5480600 doi: 10.1038/nrclinonc.2016.217

Ma R-Y, Black A, Qian B-Z. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 2022;43:546–63.

pubmed: 35690521 doi: 10.1016/j.it.2022.04.008

Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184:792–e80923.

pubmed: 33545035 doi: 10.1016/j.cell.2021.01.010

Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26:78.

pubmed: 31629410 pmcid: 6800990 doi: 10.1186/s12929-019-0568-z

de Boniface J, Mao Y, Schmidt-Mende J, Kiessling R, Poschke I. Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. OncoImmunology. 2012;1:1305–12.

pubmed: 23243594 pmcid: 3518503 doi: 10.4161/onci.21678

Rath M, Müller I, Kropf P, Closs EI, Munder M. Metabolism via Arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol. 2014;5:532.

Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70:5728–39.

pubmed: 20570887 doi: 10.1158/0008-5472.CAN-09-4672

Reeves E, James E. Antigen processing and immune regulation in the response to tumours. Immunology. 2017;150:16–24.

pubmed: 27658710 doi: 10.1111/imm.12675

Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the Tumor Microenvironment. Cell Metabol. 2019;30:36–50.

doi: 10.1016/j.cmet.2019.06.001

Viitala M, Virtakoivu R, Tadayon S, Rannikko J, Jalkanen S, Hollmén M. Immunotherapeutic blockade of Macrophage Clever-1 reactivates the CD8 + T-cell response against immunosuppressive tumors. Clin Cancer Res. 2019;25:3289–303.

pubmed: 30755440 doi: 10.1158/1078-0432.CCR-18-3016

Santoni M, Romagnoli E, Saladino T, Foghini L, Guarino S, Capponi M et al. Triple negative breast cancer: key role of Tumor-Associated macrophages in regulating the activity of anti-PD-1/PD-L1 agents. Biochimica et Biophysica Acta (BBA) - reviews on Cancer. 2018;1869:78–84.

Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227–42.

pubmed: 23470321 pmcid: 3786574 doi: 10.1038/nri3405

Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254–65.

pubmed: 11857487 doi: 10.1002/path.1027

Annacker O, Asseman C, Read S, Powrie F. Interleukin-10 in the regulation of T cell-induced colitis. J Autoimmun. 2003;20:277–9.

pubmed: 12791312 doi: 10.1016/S0896-8411(03)00045-3

Thomas DA, Massagué J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8:369–80.

pubmed: 16286245 doi: 10.1016/j.ccr.2005.10.012

Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CMT, Pryer N, et al. Macrophage IL-10 blocks CD8 + T cell-dependent responses to Chemotherapy by suppressing IL-12 expression in Intratumoral dendritic cells. Cancer Cell. 2014;26:623–37.

pubmed: 25446896 pmcid: 4254570 doi: 10.1016/j.ccell.2014.09.006

Mittal SK, Roche PA. Suppression of antigen presentation by IL-10. Curr Opin Immunol. 2015;34:22–7.

pubmed: 25597442 pmcid: 4444374 doi: 10.1016/j.coi.2014.12.009

Finetti F, Travelli C, Ercoli J, Colombo G, Buoso E, Trabalzini L. Prostaglandin E2 and Cancer: insight into Tumor Progression and Immunity. Biology. 2020;9:434.

pubmed: 33271839 pmcid: 7760298 doi: 10.3390/biology9120434

Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002;62:1676–81.

pubmed: 11912139

Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Sig Transduct Target Ther. 2021;6:362.

doi: 10.1038/s41392-021-00670-9

DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369–82.

pubmed: 30718830 pmcid: 7339861 doi: 10.1038/s41577-019-0127-6

Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, et al. Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the Tumor Microenvironment. Cancer Res. 2018;78:5011–22.

pubmed: 29967259 doi: 10.1158/0008-5472.CAN-18-0118

Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS et al. In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy. Sci Transl Med. 2017;9:eaal3604.

Krneta T, Gillgrass A, Poznanski S, Chew M, Lee AJ, Kolb M, et al. M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner. J Leukoc Biol. 2017;101:285–95.

pubmed: 27493241 doi: 10.1189/jlb.3A1215-552R

Dandekar RC, Kingaonkar AV, Dhabekar GS. Role of macrophages in malignancy. Ann Maxillofac Surg. 2011;1:150–4.

pubmed: 23482819 pmcid: 3591014 doi: 10.4103/2231-0746.92782

Herrera M, Herrera A, Domínguez G, Silva J, García V, García JM, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013;104:437–44.

pubmed: 23298232 pmcid: 7657228 doi: 10.1111/cas.12096

Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, et al. Meflin-positive Cancer-Associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res. 2019;79:5367–81.

pubmed: 31439548 doi: 10.1158/0008-5472.CAN-19-0454

Ksiazkiewicz M, Gottfried E, Kreutz M, Mack M, Hofstaedter F, Kunz-Schughart LA. Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts. Immunobiology. 2010;215:737–47.

pubmed: 20605053 doi: 10.1016/j.imbio.2010.05.019

Cohen N, Shani O, Raz Y, Sharon Y, Hoffman D, Abramovitz L, et al. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of chitinase 3-like 1. Oncogene. 2017;36:4457–68.

pubmed: 28368410 pmcid: 5507301 doi: 10.1038/onc.2017.65

Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Sem Cancer Biol. 2014;25:47–60.

doi: 10.1016/j.semcancer.2014.01.005

Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18:70.

pubmed: 30927908 pmcid: 6441236 doi: 10.1186/s12943-019-0994-2

Farhood B, Najafi M, Mortezaee K. Cancer-associated fibroblasts: secretions, interactions, and therapy. J Cell Biochem. 2019;120:2791–800.

pubmed: 30260049 doi: 10.1002/jcb.27703

Timperi E, Gueguen P, Molgora M, Magagna I, Kieffer Y, Lopez-Lastra S, et al. Lipid-Associated macrophages Are Induced by Cancer-Associated fibroblasts and mediate Immune suppression in breast Cancer. Cancer Res. 2022;82:3291–306.

pubmed: 35862581 doi: 10.1158/0008-5472.CAN-22-1427

Lei X, Lei Y, Li J-K, Du W-X, Li R-G, Yang J, et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126–33.

pubmed: 31730903 doi: 10.1016/j.canlet.2019.11.009

Chen Z, Zhou L, Liu L, Hou Y, Xiong M, Yang Y, et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. 2020;11:5077.

pubmed: 33033240 pmcid: 7545162 doi: 10.1038/s41467-020-18916-5

Zhang Y, Liu Q, Liao Q. Long noncoding RNA: a dazzling dancer in tumor immune microenvironment. J Exp Clin Cancer Res. 2020;39:231.

pubmed: 33148302 pmcid: 7641842 doi: 10.1186/s13046-020-01727-3

Qi J, Sun H, Zhang Y, Wang Z, Xun Z, Li Z, et al. Single-cell and spatial analysis reveal interaction of FAP + fibroblasts and SPP1 + macrophages in colorectal cancer. Nat Commun. 2022;13:1742.

pubmed: 35365629 pmcid: 8976074 doi: 10.1038/s41467-022-29366-6

Mazur A, Holthoff E, Vadali S, Kelly T, Post SR. Cleavage of type I collagen by fibroblast activation Protein-α enhances class A scavenger receptor mediated macrophage adhesion. PLoS ONE. 2016;11:e0150287.

pubmed: 26934296 pmcid: 4774960 doi: 10.1371/journal.pone.0150287

Ueshima E, Fujimori M, Kodama H, Felsen D, Chen J, Durack JC, et al. Macrophage-secreted TGF-β

doi: 10.1152/ajprenal.00260.2018

Yeh C-R, Slavin S, Da J, Hsu I, Luo J, Xiao G-Q, et al. Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment. Mol Cancer. 2016;15:7.

pubmed: 26790618 pmcid: 4721150 doi: 10.1186/s12943-015-0488-9

Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, et al. Pancreatic Cancer-Associated Stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-Dependent manner. Cancer Res. 2013;73:3007–18.

pubmed: 23514705 pmcid: 3785672 doi: 10.1158/0008-5472.CAN-12-4601

Hashimoto O, Yoshida M, Koma Y, Yanai T, Hasegawa D, Kosaka Y, et al. Collaboration of cancer-associated fibroblasts and tumour‐associated macrophages for neuroblastoma development. J Pathol. 2016;240:211–23.

pubmed: 27425378 pmcid: 5095779 doi: 10.1002/path.4769

Gunaydin G. CAFs interacting with TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion. Front Oncol. 2021;11:668349.

pubmed: 34336660 pmcid: 8317617 doi: 10.3389/fonc.2021.668349

Bergenfelz C, Roxå A, Mehmeti M, Leandersson K, Larsson A-M. Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer. Cancer Immunol Immunother. 2020;69:435–48.

pubmed: 31925475 pmcid: 7044142 doi: 10.1007/s00262-019-02472-z

Casbon A-J, Reynaud D, Park C, Khuc E, Gan DD, Schepers K et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci USA. 2015;112:E566–75.

Shen M, Wang J, Yu W, Zhang C, Liu M, Wang K, et al. A novel MDSC-induced PD-1

pubmed: 29632731 pmcid: 5889195 doi: 10.1080/2162402X.2017.1413520

Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, et al. Entinostat converts Immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol Res. 2018;6:1561–77.

pubmed: 30341213 pmcid: 6279584 doi: 10.1158/2326-6066.CIR-18-0070

Oh K, Lee O-Y, Shon SY, Nam O, Ryu PM, Seo MW, et al. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013;15:R79.

pubmed: 24021059 pmcid: 3979084 doi: 10.1186/bcr3473

Segovia-Mendoza M, Morales-Montor J. Immune Tumor Microenvironment in breast Cancer and the participation of Estrogen and its receptors in Cancer Physiopathology. Front Immunol. 2019;10:348.

pubmed: 30881360 pmcid: 6407672 doi: 10.3389/fimmu.2019.00348

Gelao L, Criscitiello C, Esposito A, Laurentiis MD, Fumagalli L, Locatelli MA, et al. Dendritic cell-based vaccines: clinical applications in breast cancer. Immunotherapy. 2014;6:349–60.

pubmed: 24762078 doi: 10.2217/imt.13.169

Zheng Y, Li S, Tang H, Meng X, Zheng Q. Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. Front Immunol. 2023;14:1153990.

pubmed: 37426654 pmcid: 10327275 doi: 10.3389/fimmu.2023.1153990

Liang X, Fu C, Cui W, Ober-Blöbaum JL, Zahner SP, Shrikant PA, et al. β-Catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8 + T cells. J Leukoc Biol. 2013;95:179–90.

pubmed: 24023259 doi: 10.1189/jlb.0613330

Vu SH, Vetrivel P, Kim J, Lee M-S. Cancer Resistance to Immunotherapy: Molecular mechanisms and tackling strategies. IJMS. 2022;23:10906.

pubmed: 36142818 pmcid: 9513751 doi: 10.3390/ijms231810906

Lin Y, Cai Q, Chen Y, Shi T, Liu W, Mao L, et al. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase. Hepatology. 2022;75:28–42.

pubmed: 34387870 doi: 10.1002/hep.32099

Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent Tumor Growth through Evasion of Immunity. Cell. 2015;162:1257–70.

pubmed: 26343581 pmcid: 4597191 doi: 10.1016/j.cell.2015.08.015

Liberti MV, Locasale JW. The Warburg Effect: how does it Benefit Cancer cells? Trends Biochem Sci. 2016;41:211–8.

pubmed: 26778478 pmcid: 4783224 doi: 10.1016/j.tibs.2015.12.001

Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Senbabaoglu Y, et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature. 2021;591:652–8.

pubmed: 33588426 pmcid: 8057670 doi: 10.1038/s41586-021-03326-4

Chang C-H, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the Tumor Microenvironment is a driver of Cancer Progression. Cell. 2015;162:1229–41.

pubmed: 26321679 pmcid: 4864363 doi: 10.1016/j.cell.2015.08.016

Gu J, Zhou J, Chen Q, Xu X, Gao J, Li X, et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells. Cell Rep. 2022;39:110986.

pubmed: 35732125 doi: 10.1016/j.celrep.2022.110986

Comito G, Iscaro A, Bacci M, Morandi A, Ippolito L, Parri M, et al. Lactate modulates CD4 + T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis. Oncogene. 2019;38:3681–95.

pubmed: 30664688 doi: 10.1038/s41388-019-0688-7

Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. Cutting Edge: distinct glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4 + T cell subsets. J Immunol. 2011;186:3299–303.

pubmed: 21317389 doi: 10.4049/jimmunol.1003613

Wang H, Franco F, Tsui Y-C, Xie X, Trefny MP, Zappasodi R, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol. 2020;21:298–308.

pubmed: 32066953 pmcid: 7043937 doi: 10.1038/s41590-019-0589-5

Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabol. 2006;3:187–97.

doi: 10.1016/j.cmet.2006.01.012

Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg Effect in Carcinogenesis. J Biol Chem. 2002;277:23111–5.

pubmed: 11943784 doi: 10.1074/jbc.M202487200

Kozlov AM, Lone A, Betts DH, Cumming RC. Lactate preconditioning promotes a HIF-1α-mediated metabolic shift from OXPHOS to glycolysis in normal human diploid fibroblasts. Sci Rep. 2020;10:8388.

pubmed: 32433492 pmcid: 7239882 doi: 10.1038/s41598-020-65193-9

Neumeister VM, Sullivan CA, Lindner R, Lezon-Geyda K, Li J, Zavada J, et al. Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer. Breast Cancer Res Treat. 2012;136:67–75.

pubmed: 22976806 doi: 10.1007/s10549-012-2232-0

Panisova E, Kery M, Sedlakova O, Brisson L, Debreova M, Sboarina M, et al. Lactate stimulates CA IX expression in normoxic cancer cells. Oncotarget. 2017;8:77819–35.

pubmed: 29100428 pmcid: 5652817 doi: 10.18632/oncotarget.20836

Serganova I, Cohen IJ, Vemuri K, Shindo M, Maeda M, Mane M, et al. LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response. PLoS ONE. 2018;13:e0203965.

pubmed: 30248111 pmcid: 6153000 doi: 10.1371/journal.pone.0203965

Siddiqui A, Ceppi P. A non-proliferative role of pyrimidine metabolism in cancer. Mol Metabolism. 2020;35:100962.

doi: 10.1016/j.molmet.2020.02.005

Luo Y, Tian W, Lu X, Zhang C, Xie J, Deng X, et al. Prognosis stratification in breast cancer and characterization of immunosuppressive microenvironment through a pyrimidine metabolism-related signature. Front Immunol. 2022;13:1–19.

doi: 10.3389/fimmu.2022.1056680

Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, et al. CD8 + T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med. 2023;4:100878.

pubmed: 36599350 pmcid: 9873827 doi: 10.1016/j.xcrm.2022.100878

Mao M, Chen Y, Jia Y, Yang J, Wei Q, Li Z, et al. PLCA8 suppresses breast cancer apoptosis by activating the PI3k/AKT/NF-κB pathway. J Cell Mol Med. 2019;23:6930–41.

pubmed: 31448883 pmcid: 6787500 doi: 10.1111/jcmm.14578

Mao M, Hu D, Yang J, Chen Y, Zhang X, Shen J, et al. Regulation of tamoxifen sensitivity by the PLAC8/MAPK pathway axis is antagonized by curcumin-induced protein stability change. J Mol Med. 2021;99:845–58.

pubmed: 33611659 doi: 10.1007/s00109-021-02047-5

Chen Y, Jia Y, Mao M, Gu Y, Xu C, Yang J, et al. PLAC8 promotes adriamycin resistance via blocking autophagy in breast cancer. J Cell Mol Med. 2021;25:6948–62.

pubmed: 34117724 pmcid: 8278087 doi: 10.1111/jcmm.16706

Mao M, Cheng Y, Yang J, Chen Y, Xu L, Zhang X, et al. Multifaced roles of PLAC8 in cancer. Biomark Res. 2021;9:73.

pubmed: 34627411 pmcid: 8501656 doi: 10.1186/s40364-021-00329-1

Komatsu M, Chiba T, Tatsumi K, Iemura S, Tanida I, Okazaki N, et al. A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J. 2004;23:1977–86.

pubmed: 15071506 pmcid: 404325 doi: 10.1038/sj.emboj.7600205

Yoo HM, Park JH, Jeon YJ, Chung CH. Ubiquitin-fold modifier 1 acts as a positive Regulator of breast Cancer. Front Endocrinol. 2015;6:36.

Mao M, Chen Y, Yang J, Cheng Y, Xu L, Ji F, et al. Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer. J Immunother Cancer. 2022;10:e005668.

pubmed: 36543379 pmcid: 9772693 doi: 10.1136/jitc-2022-005668

Qin G, Wang X, Ye S, Li Y, Chen M, Wang S, et al. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer. Nat Commun. 2020;11:1669.

pubmed: 32245950 pmcid: 7125142 doi: 10.1038/s41467-020-15364-z

Wang Y, Chen Y, Zhang J, Yang Y, Fleishman JS, Wang Y, et al. Cuproptosis: a novel therapeutic target for overcoming cancer drug resistance. Drug Resist Updates. 2024;72:101018.

doi: 10.1016/j.drup.2023.101018

Song S, Zhang M, Xie P, Wang S, Wang Y. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer. Front Immunol. 2022;13:1–18.

doi: 10.3389/fimmu.2022.978909

Fortis SP, Sofopoulos M, Goulielmaki M, Arnogiannaki N, Ardavanis A, Perez SA, et al. Association between Intratumoral CD8 + T cells with FoxP3 + and CD163 + cells: a potential Immune intrinsic negative feedback mechanism for Acquired Immune Resistance. Cancers. 2022;14:6208.

pubmed: 36551693 pmcid: 9777444 doi: 10.3390/cancers14246208

Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria J-C, Postel-Vinay S. Mutational Landscape and Sensitivity to Immune Checkpoint blockers. Clin Cancer Res. 2016;22:4309–21.

pubmed: 27390348 doi: 10.1158/1078-0432.CCR-16-0903

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor Mutational Burden as an independent predictor of response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017;16:2598–608.

pubmed: 28835386 pmcid: 5670009 doi: 10.1158/1535-7163.MCT-17-0386

Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74.

pubmed: 25838375 doi: 10.1126/science.aaa4971

Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482:400–4.

pubmed: 22318521 pmcid: 3874809 doi: 10.1038/nature10755

Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY. The cancer immunogram. Science. 2016;352:658–60.

pubmed: 27151852 doi: 10.1126/science.aaf2834

Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37–50.

pubmed: 16485345 doi: 10.1038/nrd1930

Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015;518:107–10.

pubmed: 25409146 doi: 10.1038/nature13905

Zhang Y, Chen J, Liu H, Mi R, Huang R, Li X, et al. The role of histone methylase and demethylase in antitumor immunity: a new direction for immunotherapy. Front Immunol. 2023;13:1–16.

doi: 10.3389/fimmu.2022.1099892

Dunn J, Rao S. Epigenetics and immunotherapy: the current state of play. Mol Immunol. 2017;87:227–39.

pubmed: 28511092 doi: 10.1016/j.molimm.2017.04.012

Khodayari S, Khodayari H, Saeedi E, Mahmoodzadeh H, Sadrkhah A, Nayernia K. Single-cell transcriptomics for unlocking Personalized Cancer Immunotherapy: toward targeting the origin of Tumor Development Immunogenicity. Cancers. 2023;15:3615.

pubmed: 37509276 pmcid: 10377122 doi: 10.3390/cancers15143615

Kim E-J, Liu P, Zhang S, Donahue K, Wang Y, Schehr JL, et al. BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity. Nucleic Acids Res. 2021;49:12211–33.

pubmed: 34865122 pmcid: 8643633 doi: 10.1093/nar/gkab1122

Lee DY, Salahuddin T, Iqbal J. Lysine-specific demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory effects in breast cancers. Curr Oncol. 2023;30:2127–43.

pubmed: 36826125 pmcid: 9955398 doi: 10.3390/curroncol30020164

Nguyen EM, Taniguchi H, Chan JM, Zhan YA, Chen X, Qiu J, et al. Targeting lysine-specific demethylase 1 rescues major histocompatibility Complex Class I Antigen Presentation and overcomes programmed death-ligand 1 Blockade Resistance in SCLC. J Thorac Oncol. 2022;17:1014–31.

pubmed: 35691495 pmcid: 9357096 doi: 10.1016/j.jtho.2022.05.014

Yu B, Luo F, Sun B, Liu W, Shi Q, Cheng S-Y, et al. KAT6A acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment, metastasis, and Immunotherapy in Triple-negative breast Cancer. Adv Sci (Weinh). 2022;9:e2105793.

pubmed: 35075800 doi: 10.1002/advs.202105793

Wong KK. DNMT1: a key drug target in triple-negative breast cancer. Sem Cancer Biol. 2021;72:198–213.

doi: 10.1016/j.semcancer.2020.05.010

Zhang Z-G, Zhang H-S, Sun H-L, Liu H-Y, Liu M-Y, Zhou Z. KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming. Exp Cell Res. 2019;379:182–90.

pubmed: 30978340 doi: 10.1016/j.yexcr.2019.04.006

Perrier A, Didelot A, Laurent-Puig P, Blons H, Garinet S. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. Biomolecules. 2020;10:1061

Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, et al. Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy. J Clin Invest. 2018;128:3813–8.

pubmed: 29905573 pmcid: 6118570 doi: 10.1172/JCI99760

Sun H-Y, Du S-T, Li Y-Y, Deng G-T, Zeng F-R. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers. World J Gastrointest Oncol. 2022;14:75–89.

pubmed: 35116104 pmcid: 8790409 doi: 10.4251/wjgo.v14.i1.75

Noblejas-López MDM, Nieto-Jimenez C, Burgos M, Gómez-Juárez M, Montero JC, Esparís-Ogando A, et al. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. J Exp Clin Cancer Res. 2019;38:383.

pubmed: 31470872 pmcid: 6717344 doi: 10.1186/s13046-019-1387-5

Qiao J, Chen Y, Mi Y, Jin H, Wang L, Huang T, et al. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE. Biochem Pharmacol. 2020;180:114126.

pubmed: 32603665 doi: 10.1016/j.bcp.2020.114126

Hicks KC, Knudson KM, Lee KL, Hamilton DH, Hodge JW, Figg WD, et al. Cooperative Immune-mediated mechanisms of the HDAC inhibitor Entinostat, an IL15 superagonist, and a Cancer Vaccine effectively synergize as a Novel Cancer Therapy. Clin Cancer Res. 2020;26(3):704–16.

pubmed: 31645354 doi: 10.1158/1078-0432.CCR-19-0727

Joyce OS, et al. Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC). JCO. 2020;38:1014–1014.

doi: 10.1200/JCO.2020.38.15_suppl.1014

Roussos Torres ET, Ho WJ, Danilova L, Tandurella JA, Leatherman J, Rafie C et al. Entinostat, Nivolumab and Ipilimumab for women with advanced HER2-negative breast cancer: a phase ib trial. Nat Cancer. 2024 Feb 14. Epub ahead of print.

Jiang X, Qian Z, Chen Y, Zhou T, Zhao C, Yin Y. CMTM7 recognizes an immune-hot tumor microenvironment and predicts therapeutic response of immunotherapy in breast cancer well. Front Genet. 2022;13:1–15.

doi: 10.3389/fgene.2022.1051269

Wu C, Zhong R, Sun X, Shi J. PSME2 identifies immune-hot tumors in breast cancer and associates with well therapeutic response to immunotherapy. Front Genet. 2022;13:1–12.

doi: 10.3389/fgene.2022.1071270

Li RQ, Wang W, Yan L, Song LY, Guan X, Zhang W, et al. Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development. Front Oncol. 2022;12:1–17.

Zavareh RB, Spangenberg SH, Woods A, Martínez-Peña F, Lairson LL. HSP90 inhibition enhances Cancer Immunotherapy by modulating the Surface expression of multiple Immune Checkpoint proteins. Cell Chem Biology. 2021;28:158–e1685.

doi: 10.1016/j.chembiol.2020.10.005

Rahmy S, Mishra SJ, Murphy S, Blagg BSJ, Lu X. Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors. Front Immunol. 2022;13:1005045.

Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, et al. HSP90 inhibition is effective in breast Cancer: a phase II trial of Tanespimycin (17-AAG) plus trastuzumab in patients with HER2-Positive metastatic breast Cancer progressing on Trastuzumab. Clin Cancer Res. 2011;17:5132–9.

pubmed: 21558407 doi: 10.1158/1078-0432.CCR-11-0072

Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel inhibitor of heat shock protein 90, in patients with Refractory Advanced cancers. Clin Cancer Res. 2005;11:3385–91.

pubmed: 15867239 doi: 10.1158/1078-0432.CCR-04-2322

Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, et al. TNFα-Induced Mucin 4 expression elicits Trastuzumab Resistance in HER2-Positive breast Cancer. Clin Cancer Res. 2017;23:636–48.

pubmed: 27698002 doi: 10.1158/1078-0432.CCR-16-0970

Carraway KL, Rossi EA, Komatsu M, Price-Schiavi SA, Huang D, Guy PM, et al. An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates Neuregulin Signaling. J Biol Chem. 1999;274:5263–6.

pubmed: 10026131 doi: 10.1074/jbc.274.9.5263

Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer. 2002;99:783–91.

pubmed: 12115478 doi: 10.1002/ijc.10410

Bruni S, Mauro FL, Proietti CJ, Cordo-Russo RI, Rivas MA, Inurrigarro G, et al. Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. J Immunother Cancer. 2023;11:e005325.

pubmed: 36889811 pmcid: 10016294 doi: 10.1136/jitc-2022-005325

Yi M, Niu M, Wu Y, Ge H, Jiao D, Zhu S, et al. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. J Hematol Oncol. 2022;15:142.

pubmed: 36209176 pmcid: 9548169 doi: 10.1186/s13045-022-01363-8

Santinon F, Ezzahra BF, Bachais M, Sarabia Pacis A, Rudd CE. Direct AKT activation in tumor-infiltrating lymphocytes markedly increases interferon-γ (IFN-γ) for the regression of tumors resistant to PD-1 checkpoint blockade. Sci Rep. 2022;12:18509.

pubmed: 36323740 pmcid: 9630443 doi: 10.1038/s41598-022-23016-z

Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M-K, Hsu J-M, et al. PARP inhibitor upregulates PD-L1 expression and enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017;23:3711–20.

pubmed: 28167507 pmcid: 5511572 doi: 10.1158/1078-0432.CCR-16-3215

Li B, Tao W, Shao-hua Z, Ze-rui Q, Fu-quan J, Fan L, et al. Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy. Cancer Biol Ther. 2018;19:292–5.

pubmed: 29333945 pmcid: 5902233 doi: 10.1080/15384047.2017.1414761

Mishra A, Kumar D, Gupta K, Lofland G, Sharma AK, Banka DS, et al. Gallium-68–labeled peptide PET quantifies Tumor exposure of PD-L1 therapeutics. Clin Cancer Res. 2023;29:581–91.

pubmed: 36449662 doi: 10.1158/1078-0432.CCR-22-1931

Main SC, Cescon DW, Bratman SV. Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer. Cancer Drug Resist. 2022;5:727–48.

pubmed: 36176758 pmcid: 9511796 doi: 10.20517/cdr.2022.37

Chin YM, Shibayama T, Chan HT, Otaki M, Hara F, Kobayashi T, et al. Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer Sci. 2022;113:1808–20.

pubmed: 35201661 pmcid: 9128178 doi: 10.1111/cas.15304

Ford K, Hanley CJ, Mellone M, Szyndralewiez C, Heitz F, Wiesel P, et al. NOX4 inhibition potentiates immunotherapy by overcoming Cancer-Associated fibroblast-mediated CD8 T-cell exclusion from tumors. Cancer Res. 2020;80:1846–60.

pubmed: 32122909 pmcid: 7611230 doi: 10.1158/0008-5472.CAN-19-3158

Hanley CJ, Mellone M, Ford K, Thirdborough SM, Mellows T, Frampton SJ, et al. Targeting the Myofibroblastic Cancer-Associated Fibroblast phenotype through inhibition of NOX4. JNCI: J Natl Cancer Inst. 2018;110:109–20.

pubmed: 28922779 doi: 10.1093/jnci/djx121

Hanley CJ, Thomas GJ. T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting. Br J Cancer. 2020;123:1353–5.

pubmed: 32830198 pmcid: 7591574 doi: 10.1038/s41416-020-1020-6

Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9(1):4692.

pubmed: 30410077 pmcid: 6224529 doi: 10.1038/s41467-018-06654-8

Mhaidly R, Mechta-Grigoriou F. Role of cancer‐associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol Rev. 2021;302:259–72.

pubmed: 34013544 pmcid: 8360036 doi: 10.1111/imr.12978

Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, et al. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci USA. 2019;116:4558–66.

pubmed: 30700545 pmcid: 6410779 doi: 10.1073/pnas.1815515116

Glabman RA, Choyke PL, Sato N. Cancer-Associated fibroblasts: Tumorigenicity and Targeting for Cancer Therapy. Cancers. 2022;14:3906.

pubmed: 36010899 pmcid: 9405783 doi: 10.3390/cancers14163906

Rizzolio S, Giordano S, Corso S. The importance of being CAFs (in cancer resistance to targeted therapies). J Exp Clin Cancer Res. 2022;41:319.

pubmed: 36324182 pmcid: 9632140 doi: 10.1186/s13046-022-02524-w

Monteran L, Erez N. The Dark side of fibroblasts: Cancer-Associated fibroblasts as mediators of Immunosuppression in the Tumor Microenvironment. Front Immunol. 2019;10:1835.

pubmed: 31428105 pmcid: 6688105 doi: 10.3389/fimmu.2019.01835

Binnewies M, Pollack JL, Rudolph J, Dash S, Abushawish M, Lee T, et al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 2021;37:109844.

pubmed: 34686340 doi: 10.1016/j.celrep.2021.109844

Flores-Toro JA, Luo D, Gopinath A, Sarkisian MR, Campbell JJ, Charo IF et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proceedings of the National Academy of Sciences. 2020;117:1129–38.

Zhu Y, Herndon JM, Sojka DK, Kim K-W, Knolhoff BL, Zuo C, et al. Tissue-Resident macrophages in Pancreatic Ductal Adenocarcinoma Originate from embryonic hematopoiesis and promote Tumor Progression. Immunity. 2017;47:323–e3386.

pubmed: 28813661 pmcid: 5578409 doi: 10.1016/j.immuni.2017.07.014

Soncin I, Sheng J, Chen Q, Foo S, Duan K, Lum J, et al. The tumour microenvironment creates a niche for the self-renewal of tumour-promoting macrophages in colon adenoma. Nat Commun. 2018;9:582.

pubmed: 29422500 pmcid: 5805689 doi: 10.1038/s41467-018-02834-8

Bassez A, Vos H, Van Dyck L, Floris G, Arijs I, Desmedt C, et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 2021;27:820–32.

pubmed: 33958794 doi: 10.1038/s41591-021-01323-8

Nalio Ramos R, Missolo-Koussou Y, Gerber-Ferder Y, Bromley CP, Bugatti M, Núñez NG, et al. Tissue-resident FOLR2 + macrophages associate with CD8 + T cell infiltration in human breast cancer. Cell. 2022;185:1189–e120725.

pubmed: 35325594 doi: 10.1016/j.cell.2022.02.021

Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting Tumor-Associated macrophages with Anti-CSF-1R antibody reveals a strategy for Cancer Therapy. Cancer Cell. 2014;25:846–59.

pubmed: 24898549 doi: 10.1016/j.ccr.2014.05.016

Uhlik MT, Harrison B, Gorden K, Leonardo S, Walsh R, Ertelt K, et al. Abstract LB-129: Imprime PGG, a soluble yeast β-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients. Cancer Res. 2018;78(13Supplement):LB–129.

Anfray U. Andón, Allavena. Current strategies to Target Tumor-Associated-macrophages to improve Anti-tumor Immune responses. Cells. 2019;9:46.

pubmed: 31878087 pmcid: 7017001 doi: 10.3390/cells9010046

Zhu J, Zhang Y, Zhang A, He K, Liu P, Xu LX. Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation. Sci Rep. 2016;6:27136.

pubmed: 27256519 pmcid: 4891716 doi: 10.1038/srep27136

Lou Y, Peng P, Wang S, Wang J, Du P, Zhang Z, et al. Combining all-trans retinoid acid treatment targeting myeloid-derived suppressive cells with cryo-thermal therapy enhances antitumor immunity in breast cancer. Front Immunol. 2022;13:1–14.

doi: 10.3389/fimmu.2022.1016776

Colligan SH, Amitrano AM, Zollo RA, Peresie J, Kramer ED, Morreale B, et al. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression. J Clin Invest. 2022;132:1–17.

doi: 10.1172/JCI158661

Horvat NK, Lesinski GB. Bring on the brequinar: an approach to enforce the differentiation of myeloid-derived suppressor cells. J Clin Invest. 2022;132:1–3.

doi: 10.1172/JCI165506

Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, Córdoba A, de Azúa YR, Aguiar B, et al. ADAM12 is a potential therapeutic target regulated by Hypomethylation in Triple-negative breast Cancer. IJMS. 2020;21:903.

pubmed: 32019179 pmcid: 7036924 doi: 10.3390/ijms21030903

Wang G, Romero Y, Thevarajan I, Zolkiewska A. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer. OncoImmunology. 2023;12:2158006.

pubmed: 36545255 doi: 10.1080/2162402X.2022.2158006

Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20:516–31.

pubmed: 32632251 pmcid: 8041116 doi: 10.1038/s41568-020-0273-y

Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of T cell longevity and function in Tumor Immunotherapy. Cell Metabol. 2017;26:94–109.

doi: 10.1016/j.cmet.2017.06.016

Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW. Programmed cell death Ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res. 2018;6:1260–73.

pubmed: 30012633 doi: 10.1158/2326-6066.CIR-17-0537

Wang Y, Wang Y, Ren Y, Zhang Q, Yi P, Cheng C. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Sem Cancer Biol. 2022;86:542–65.

doi: 10.1016/j.semcancer.2022.02.010

Sansom DM. CD28, CTLA-4 and their ligands: who does what and to whom? The effects of CD28 and CTLA-4 ligands. Immunology. 2000;101:169–77.

pubmed: 11012769 pmcid: 2327073 doi: 10.1046/j.1365-2567.2000.00121.x

Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 Signaling Pathway regulates glucose metabolism. Immunity. 2002;16:769–77.

pubmed: 12121659 doi: 10.1016/S1074-7613(02)00323-0

Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-Cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543–53.

pubmed: 16227604 pmcid: 1265804 doi: 10.1128/MCB.25.21.9543-9553.2005

Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV, et al. Regulatory T cells exhibit distinct features in human breast Cancer. Immunity. 2016;45:1122–34.

pubmed: 27851913 pmcid: 5134901 doi: 10.1016/j.immuni.2016.10.032

Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, et al. Aerobic glycolysis controls myeloid-derived suppressor cells and Tumor Immunity via a specific CEBPB isoform in Triple-negative breast Cancer. Cell Metabol. 2018;28:87–e1036.

doi: 10.1016/j.cmet.2018.04.022

Rizwan A, Serganova I, Khanin R, Karabeber H, Ni X, Thakur S, et al. Relationships between LDH-A, Lactate, and metastases in 4T1 breast tumors. Clin Cancer Res. 2013;19:5158–69.

pubmed: 23833310 doi: 10.1158/1078-0432.CCR-12-3300

Gong Y, Ji P, Yang Y-S, Xie S, Yu T-J, Xiao Y, et al. Metabolic-pathway-based subtyping of Triple-negative breast Cancer reveals potential therapeutic targets. Cell Metabol. 2021;33:51–e649.

doi: 10.1016/j.cmet.2020.10.012

Chafe SC, McDonald PC, Saberi S, Nemirovsky O, Venkateswaran G, Burugu S, et al. Targeting Hypoxia-Induced Carbonic anhydrase IX enhances Immune-Checkpoint Blockade locally and systemically. Cancer Immunol Res. 2019;7:1064–78.

pubmed: 31088846 doi: 10.1158/2326-6066.CIR-18-0657

Hedlund MD. Nemirovsky, Awrey, Jensen, Dedhar. Harnessing Induced Essentiality: Targeting Carbonic anhydrase IX and Angiogenesis reduces Lung Metastasis of Triple negative breast Cancer xenografts. Cancers. 2019;11:1002.

pubmed: 31319613 pmcid: 6678951 doi: 10.3390/cancers11071002

Jin H, Liao S, Yao F, Li J, Xu Z, Zhao K, et al. Insight into the crosstalk between photodynamic therapy and immunotherapy in breast Cancer. Cancers. 2023;15:1532.

pubmed: 36900322 pmcid: 10000400 doi: 10.3390/cancers15051532

Taber SW, Fingar VH, Coots CT, Wieman TJ. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a phase I clinical study. Clin Cancer Res. 1998;4:2741–6.

pubmed: 9829737

Vrouenraets MB, Visser GWM, Snow GB, van Dongen GAMS. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res. 2003;23:505–22.

pubmed: 12680139

Anzengruber F, Avci P, De Freitas LF, Hamblin MR. T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it? Photochem Photobiol Sci. 2015;14:1492–509.

pubmed: 26062987 pmcid: 4547550 doi: 10.1039/c4pp00455h

Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, et al. 5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. Eur J Cancer. 2014;50:1370–81.

pubmed: 24559534 pmcid: 4136636 doi: 10.1016/j.ejca.2014.01.017

Soman S, Kulkarni S, Pandey A, Dhas N, Subramanian S, Mukherjee A, et al. 2D hetero-nanoconstructs of black phosphorus for breast Cancer theragnosis: Technological advancements. Biosensors. 2022;12:1009.

pubmed: 36421127 pmcid: 9688887 doi: 10.3390/bios12111009

Gogoi M, Sarma HD, Bahadur D, Banerjee R. Biphasic magnetic nanoparticles–nanovesicle hybrids for chemotherapy and self-controlled hyperthermia. Nanomedicine. 2014;9:955–70.

pubmed: 24102326 doi: 10.2217/nnm.13.90

Li Z, Hu Y, Fu Q, Liu Y, Wang J, Song J, et al. NIR/ROS-Responsive Black Phosphorus QD Vesicles as immunoadjuvant carrier for specific Cancer photodynamic immunotherapy. Adv Funct Mater. 2020;30:1905758.

doi: 10.1002/adfm.201905758

Liang X, Ye X, Wang C, Xing C, Miao Q, Xie Z, et al. Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation. J Controlled Release. 2019;296:150–61.

doi: 10.1016/j.jconrel.2019.01.027

Zhao P, Xu Y, Ji W, Zhou S, Li L, Qiu L, et al. Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer. J Nanobiotechnol. 2021;19:181.

doi: 10.1186/s12951-021-00932-2

Zhang X, Tang J, Li C, Lu Y, Cheng L, Liu J. A targeting black phosphorus nanoparticle based immune cells nano-regulator for photodynamic/photothermal and photo-immunotherapy. Bioactive Mater. 2021;6:472–89.

doi: 10.1016/j.bioactmat.2020.08.024

Wang X, Tokheim C, Gu SS, Wang B, Tang Q, Li Y, et al. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell. 2021;184:5357–e537422.

pubmed: 34582788 pmcid: 9136996 doi: 10.1016/j.cell.2021.09.006

Ji P, Gong Y, Jin ML, Wu HL, Guo LW, Pei YC et al. In Vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. Sci Adv. 2022;8:eabl8247.

Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, et al. Systematic Immunotherapy Target Discovery using genome-scale in vivo CRISPR screens in CD8 T cells. Cell. 2019;178:1189–e120423.

pubmed: 31442407 pmcid: 6719679 doi: 10.1016/j.cell.2019.07.044

Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547:413–8.

pubmed: 28723893 pmcid: 5924693 doi: 10.1038/nature23270

Kim S-S, Harford JB, Moghe M, Rait A, Chang EH. Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor. OncoImmunology. 2018;7:e1484982.

pubmed: 30288347 pmcid: 6169574 doi: 10.1080/2162402X.2018.1484982

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-negative breast Cancer. N Engl J Med. 2018;379:2108–21.

pubmed: 30345906 doi: 10.1056/NEJMoa1809615

Dai L, Li K, Li M, Zhao X, Luo Z, Lu L, et al. Size/Charge changeable acidity-responsive micelleplex for photodynamic‐improved PD‐L1 immunotherapy with enhanced tumor penetration. Adv Funct Mater. 2018;28:1707249.

doi: 10.1002/adfm.201707249

Kang T, Li Y, Wang Y, Zhu J, Yang L, Huang Y, et al. Modular Engineering of targeted dual-drug nanoassemblies for Cancer Chemoimmunotherapy. ACS Appl Mater Interfaces. 2019;11:36371–82.

pubmed: 31490057 doi: 10.1021/acsami.9b11881

Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016;11:986–94.

pubmed: 27668795 pmcid: 5198777 doi: 10.1038/nnano.2016.168

Pal R, Chakraborty B, Nath A, Singh LM, Ali M, Rahman DS, et al. Noble metal nanoparticle-induced oxidative stress modulates tumor associated macrophages (TAMs) from an M2 to M1 phenotype: an in vitro approach. Int Immunopharmacol. 2016;38:332–41.

pubmed: 27344639 doi: 10.1016/j.intimp.2016.06.006

Zhang Y, Chen H, Mo H, Hu X, Gao R, Zhao Y, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021;39:1578–e15938.

pubmed: 34653365 doi: 10.1016/j.ccell.2021.09.010

Tietscher S, Wagner J, Anzeneder T, Langwieder C, Rees M, Sobottka B, et al. A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nat Commun. 2023;14:98.

pubmed: 36609566 pmcid: 9822999 doi: 10.1038/s41467-022-35238-w

Ma C, Yang C, Peng A, Sun T, Ji X, Mi J, et al. Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment. Mol Cancer. 2023;22(1):170.

doi: 10.1186/s12943-023-01876-x pubmed: 37833788 pmcid: 10571470

Li C, Yang L, Zhang Y, Hou Q, Wang S, et al. Integrating single-cell and bulk transcriptomic analyses to develop a cancer-associated fibroblast-derived biomarker for predicting prognosis and therapeutic response in breast cancer. Front Immunol. 2024;14:1307588.

pubmed: 38235137 pmcid: 10791883 doi: 10.3389/fimmu.2023.1307588

Rodriguez-Garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, O’Connor RS, et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun. 2021;12(1):877.

pubmed: 33563975 pmcid: 7873057 doi: 10.1038/s41467-021-20893-2

Chuangchot N, Jamjuntra P, Yangngam S, Luangwattananun P, Thongchot S, Junking M, et al. Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways. Breast Cancer Res. 2023;25(1):86.

pubmed: 37480115 pmcid: 10362675 doi: 10.1186/s13058-023-01684-7

Chen Y, Shu X, Guo JY, Xiang Y, Liang SY, Lai JM, et al. Nanodrugs mediate TAMs-related arginine metabolism interference to boost photodynamic immunotherapy. J Control Release. 2024;367:248–64.

pubmed: 38272398 doi: 10.1016/j.jconrel.2024.01.045

Marta Warszyńska JM, Dąbrowski. Photodynamic therapy combined with immunotherapy: Recent advances and future research directions. Coordination Chemistry Reviews, 495, 2023, 215350.

Johnson DB, Reynolds KL, Sullivan RJ, Balko JM, Patrinely JR, et al. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncol. 2020;21(8):e398–404.

pubmed: 32758477 doi: 10.1016/S1470-2045(20)30107-8

Oliver AJ, Lau PKH, Unsworth AS, Loi S, Darcy PK, Kershaw MH, et al. Tissue-dependent tumor microenvironments and their impact on immunotherapy responses. Front Immunol. 2018;9:70.

pubmed: 29445373 pmcid: 5797771 doi: 10.3389/fimmu.2018.00070

Chaudhuri S, Thomas S, Munster P. Immunotherapy in breast cancer: a clinician’s perspective. J Natl Cancer Cent. 2021;1:47–57.

doi: 10.1016/j.jncc.2021.01.001

Gui C-P, Wei J-H, Zhang C, Tang Y-M, Shu G-N, Wu R-P, et al. Single-cell and spatial transcriptomics reveal 5-methylcytosine RNA methylation regulators immunologically reprograms tumor microenvironment characterizations, immunotherapy response and precision treatment of clear cell renal cell carcinoma. Translational Oncol. 2023;35:101726.

doi: 10.1016/j.tranon.2023.101726

Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Pagination

Subventions

Informations de copyright

Références

Auteurs

Moumita Kundu (M)

Ramesh Butti (R)

Venketesh K Panda (VK)

Diksha Malhotra (D)

Sumit Das (S)

Tandrima Mitra (T)

Prachi Kapse (P)

Suresh W Gosavi (SW)

Gopal C Kundu (GC)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH